Pink Sheet Senior Writer Derrick Gingery, senior editors Sue Sutter and Brenda Sandburg, and Executive Editor Nielsen Hobbs discuss the take-aways from Moderna, Inc. CEO Stéphane Bancel’s appearance at a Senate hearing on COVID-19 vaccine pricing, the National Institutes of Health not considering drug pricing in the march-in rights case for Astellas Pharma, Inc. and Pfizer Inc.’s prostate cancer treatment Xtandi (enzalutamide), and the type of approval that Biogen, Inc. and Ionis Pharmaceuticals, Inc.’s ALS candidate Qalsody (tofersen) could receive from the US Food and Drug Administration.
Pink Sheet Podcast: Moderna CEO On Capitol Hill, Xtandi March-In Rights, Tofersen Adcomm In ALS
Pink Sheet reporter and editors discuss Moderna CEO’s Stéphane Bancel’s defense of his company and COVID-19 vaccine pricing at the Senate Health, Education, Labor and Pensions Committee, the NIH denying a petition to use government march-in rights for Xtandi, and Tofersen receiving a positive US FDA advisory committee recommendation for use in ALS.
